Veterinary Medicines

Bovaclox DC Xtra Intramammary Suspension

Authorised
  • Ampicillin trihydrate
  • Cloxacillin hemibenzathine
Download as PDF

Product identification

Medicine name:
Bovaclox DC Xtra Intramammary Suspension
Active substance:
  • Ampicillin trihydrate
  • Cloxacillin hemibenzathine
Target species:
  • Cattle
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Ampicillin trihydrate
    346.45
    milligram(s)
    /
    1.00
    Syringe
  • Cloxacillin hemibenzathine
    1530.76
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary suspension
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle
      • Meat and offal
        28
        day
      • Milk
        156
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51CR50
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Available in:
  • Ireland
Package description:
  • Bovaclox DC Xtra is presented in high density polyethylene syringes (with high density polyethylene caps) containing 5.4g of an off-white non aqueous suspension. These intramammary syringes will be supplied in buckets of 120 syringes
  • Bovaclox DC Xtra is presented in high density polyethylene syringes (with high density polyethylene caps) containing 5.4g of an off-white non aqueous suspension. These intramammary syringes will be supplied in cartons of 24 syringes

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Norbrook Laboratories (Ireland) Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Norbrook Laboratories Limited
  • Norbrook Manufacturing Limited
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA22664/038/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 30/03/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."